Clinical and Translational Medicine

Clinical and Translational Medicine is a fully open access monthly journal published by Wiley since 2020 and previously by Springer, founded in 2012 to speed the translation of preclinical research into clinical application, with a 2025 Journal Impact Factor of 7.9 and a rank of 25 of 191 in medicine, research and experimental《临床与转化医学》（Clinical and Translational Medicine）是（Wiley）自 2020 年起出版、此前由（Springer）出版的完全开放获取月刊，2012 年创刊，旨在加快临床前研究向临床应用的转化，2025 年影响因子为 7.9，在医学研究与实验类 191 种期刊中列第 25 位。

Scope

• The journal follows a bench-to-bedside approach and favours studies and clinical observations that generate hypotheses about patients and disease and guide cellular and molecular medicine该刊遵循从实验台到病床的路径，偏重能就患者与疾病提出问题并指导细胞与分子医学研究的试验和临床观察。
• Education and career development in translational medicine form one of its themed areas转化医学领域的教育与职业发展是该刊的主题方向之一。
• Clinical studies of drugs and devices, and target-based drug discovery and development, are core content药物与器械的临床研究以及基于靶点的药物发现与开发是核心内容。
• Clinical bioinformatics and clinical trans-omics are treated as distinct subject areas临床生物信息学与临床跨组学被列为独立学科方向。
• Single-cell biomedicine, stem cell biology and therapy, and clinical genomics each have a dedicated stream单细胞生物医学、干细胞生物学与治疗、临床基因组学各有专门方向。
• Vaccines and immunotherapy, and chronic metabolic disease, complete the list of themed topics疫苗与免疫治疗以及慢性代谢性疾病构成主题方向的其余部分。
• Submissions are invited from clinicians, researchers, policy makers and industry, reflecting the journal's wish to connect basic and clinical scientists该刊面向临床医师、研究者、决策者与产业界征稿，体现其连接基础与临床科学家的取向。

History

• The journal was founded in 2012 under Springer, and its first articles appeared in March 2012 in volume 1该刊于 2012 年在（Springer）旗下创办，首批文章于 2012 年 3 月在第 1 卷刊出。
• Publication transferred to Wiley with effect from 21 February 2020, and Springer retained the archive of earlier volumes出版工作自 2020 年 2 月 21 日起转由（Wiley）承担，此前各卷的存档仍由（Springer）保留。
• It is published monthly and reached volume 16 in 2026, with an issue for each month该刊按月出版，2026 年已出至第 16 卷，每月一期。
• It is fully open access, publishing under a Creative Commons attribution licence and charging an article processing charge该刊为完全开放获取，按知识共享署名许可发表并收取文章处理费。
• Impact factors were 11.492 in 2021, 8.554 in 2022, 6.8 in 2024 and 7.9 in 2025影响因子为 2021 年 11.492、2022 年 8.554、2024 年 6.8、2025 年 7.9。
• In 2025 it ranked 25th of 191 in medicine, research and experimental at the 87.2nd percentile and 45th of 333 in oncology, with an acceptance rate of about 10 per cent and a median of seven days to first decision2025 年该刊在医学研究与实验类 191 种期刊中列第 25 位，百分位 87.2，在肿瘤学类 333 种期刊中列第 45 位，录用率约 10%，首次决定中位时间为 7 天。

Editors

• The editor-in-chief is Xiangdong Wang, professor of medicine at Fudan University and director of the Shanghai Institute of Clinical Bioinformatics主编为（Fudan University）医学教授、上海临床生物信息学研究所所长 Xiangdong Wang。
• The journal is affiliated with the International Society for Translational Medicine and with the Shanghai Institute of Clinical Bioinformatics, which acts as its editorial base该刊与（International Society for Translational Medicine）及上海临床生物信息学研究所相关联，后者是其编辑基地。
• An international advisory board includes Ambroise Wonkam of the University of Cape Town, Anne Chang of the Menzies School of Health Research and Julio Licinio of Flinders University国际顾问委员会包括（University of Cape Town）的 Ambroise Wonkam、（Menzies School of Health Research）的 Anne Chang 与（Flinders University）的 Julio Licinio。
• Further advisers include Francesco Marincola, Lennart Hammarstrom of the Karolinska Institute and Mariusz Ratajczak of the University of Louisville其他顾问包括 Francesco Marincola、（Karolinska Institute）的 Lennart Hammarstrom 与（University of Louisville）的 Mariusz Ratajczak。
• Manuscripts are peer reviewed externally, and the journal indexes its content in MEDLINE, PubMed Central, SCIE, Embase and the Directory of Open Access Journals稿件由外部同行评审，该刊内容被（MEDLINE）、（PubMed Central）、（SCIE）、（Embase）与（Directory of Open Access Journals）收录。